Literature DB >> 19225450

Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems.

A Carvajal1, D Macías, I Salado, M Sáinz, S Ortega, C Campo, J García del Pozo, L H Martín Arias, A Velasco, S Gonçalves, R Pombal, R Carmona.   

Abstract

We searched the Spanish and Portuguese pharmacovigilance databases for spontaneous case reports of heart rhythm disturbances associated with rupatadine and other new H1 antihistamines. Five cases were found involving patients treated with rupatadine (13.9% of all reports relating to this drug). In all five cases, the reaction started after exposure and resolved when the drug was discontinued. In two cases, rupatadine was the only medication being taken by the patient, and no other condition that could explain the heart rhythm disturbances was diagnosed. The reporting odds ratio was 3.2 (95% confidence interval, 1.0-10.5). The reporting rate was 2 cases per 100,000 patients treated per year (95% confidence interval, 0.4-6.0). These results suggest a causal relationship between rupatadine and heart rhythm disturbances.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225450     DOI: 10.1038/clpt.2008.269

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Authors:  Elisabetta Poluzzi; I Diemberger; M De Ridder; A Koci; M Clo; A Oteri; S Pecchioli; I Bezemer; T Schink; S Pilgaard Ulrichsen; G Boriani; M C J Sturkenboom; F De Ponti; G Trifirò
Journal:  Eur J Clin Pharmacol       Date:  2017-08-22       Impact factor: 2.953

2.  No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Authors:  Ester Donado; Iñaki Izquierdo; Iñaki Pérez; Olga García; Rosa M Antonijoan; Ignaci Gich; Anna Solans; Juana Peña; Joel Morganroth; Manuel J Barbanoj
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.